Enrichment of shRNA at day 14 compared to day 0 indicated that it targeted an anti-growth gene, while depletion of a shRNA suggested it targeted a pro-growth gene (e.g., shRNAs targeting BRAF in melanoma, Supplementary Fig. 4). This evidence concerns the gene BRAF and melanoma.